151. Abstract A28: Rapamycin-upregulated miR-29b promotes mTORC1-hyperactivative cell growth by downregulating retinoic acid receptor β (RARβ)
- Author
-
Heng-Jia Liu, Alex K. Conttrill, Hilaire C. Lam, Elizabeth P. Henske, Christian V. Baglini, and Stephen Y. Chan
- Subjects
congenital, hereditary, and neonatal diseases and abnormalities ,Cancer Research ,business.industry ,Cell growth ,Autophagy ,mTORC1 ,medicine.disease ,Retinoic acid receptor ,Tuberous sclerosis ,medicine.anatomical_structure ,Oncology ,Cancer research ,Medicine ,TSC1 ,TSC2 ,business ,Molecular Biology ,PI3K/AKT/mTOR pathway - Abstract
Tuberous sclerosis complex (TSC) is an incurable multisystem disease associated with hamartomatous tumors of brain, heart, skin, kidney and lung. The TSC proteins (TSC1 and TSC2) inhibit the mechanistic/mammalian target of rapamycin complex 1 (mTORC1), an exquisitely sensitive molecular sensor that regulates cell growth, cell metabolism and autophagy. mTORC1 is hyperactive in many malignancies, including TSC. Treatment of TSC-associated tumors with mTOR inhibitors leads to partial responses, with prompt regrowth upon treatment cessation, highlighting the unmet clinical need for cytocidal therapies. We previously discovered that miR-29b expression is strongly upregulated following rapamycin treatment. However, the functional significance and therapeutic impact of miR-29b induction by rapamycin in the therapy of TSC is unknown. We found that miR-29b expression is induced by rapamycin in vitro in 4 different TSC2-deficient cells and in vivo TSC-2 deficient tumors. Inhibition of miR-29b significantly decreased anchorage-independent cell growth by 40% (p < 0.01), and combined rapamycin treatment and miR-29b inhibition further suppressed growth by 73% (p < 0.0001). In addition, miR-29b knockdown inhibited cell migration and invasion by 68% (p < 0.05) and 50% (p < 0.01), respectively. miR-29b inhibition combined with rapamycin further decreased cell migration and invasion by 77% (p < 0.001) and 74% (p < 0.001), respectively. These findings suggest that miR-29b acts as an “onco-miR” in this context. Importantly, miR-29b knockdown in TSC2-deficient cells significantly suppressed tumorigenesis in vivo by 52% (p < 0.0001). Furthermore, the combination of rapamycin and miR-29b inhibition resulted in a more robust inhibition of tumor volume compared with miR control (47% vs. 24% inhibition) (p < 0.01). To gain insight into the molecular mechanisms by which miR-29b promotes tumorigenesis, we performed RNA-sequencing on miR-29b knockdown and control cells treated with rapamycin. 236 genes were upregulated in miR-29b knockdown cells by at least 2.0-fold and p < 0.05. Retinoid receptor beta (RARβ), one of the candidates, was increased in miR-29b knockdown cells at the mRNA level by 2.25-fold (p < 0.01) and protein expression by 2-fold (p < 0.05). RARβ is a tumor suppressor in many types of tumors. Interestingly, RARβ expression is downregulated by rapamycin (67% (p < 0.001)) and upregulated 4-fold following miR-29b inhibition (p < 0.05). Lastly, we found the 3'UTR activity of RARβ was upregulated in miR-29b knockdown cells by 4-fold (p < 0.001) using a luciferase reporter assay, supporting a model in which RARβ is a direct target of miR-29b. These studies demonstrate that miR-29b induction by rapamycin promotes TSC2-deficient tumorigenesis. miR-29b is a potential therapeutic target for TSC-associated tumors and possibly other mTORC-1 hyperactive tumors. Citation Format: Heng-Jia Liu, Hilaire C. Lam, Christian V. Baglini, Alex K. Conttrill, Stephen Y. Chan, Elizabeth P. Henske. Rapamycin-upregulated miR-29b promotes mTORC1-hyperactivative cell growth by downregulating retinoic acid receptor β (RARβ) [abstract]. In: Proceedings of the AACR Special Conference on Targeting PI3K/mTOR Signaling; 2018 Nov 30-Dec 8; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Res 2020;18(10_Suppl):Abstract nr A28.
- Published
- 2020